Sarclisa regimen reduced risk of disease progression or death by 45% compared to standard of care in patients who had relapsed after one to three prior therapies
While the median progression free survival (PFS) for Sarclisa combination therapy is not yet reached, consistent improvement in PFS is seen across patient subgroups
This is the second FDA approval for Sarclisa in combination with standard of care backbone therapies
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.